issued
on 12 Mar 2024
Last Applicant/ Owned by
75 Hayden Avenue
Lexington
MA
02421
Serial Number
90458999 filed on 11th Jan 2021
Registration Number
N/A
Correspondent Address
Bridget H. Labutta
Panitch Schwarze Belisario & Nadel LLP
2001 Market Street, Suite 2800
Two Commerce Square
Philadelphia,PA 19103
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
Research and development of oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections; research and development of pharmaceutical preparations for the treatment of disorders outside the liver; research and development of oligonucleotide compounds for targeted gene silencing; research aRead More
Research and development of oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections; research and development of pharmaceutical preparations for the treatment of disorders outside the liver; research and development of oligonucleotide compounds for targeted gene silencing; research and development of oligonucleotide drug delivery platforms for use in the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections
Oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections; Oligonucleotide delivery agents consisting of compounds that facilitate the delivery of a wide range of pharmaceutical and therapeutic agents intravenously or subcutaneously for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections; Oligonucleotide compounds for use in the targeted delivery of RNA interference (RNAi) therapy; Oligonucleotide delivery agents consisting of compounds that facilitate the delivery of a wide range of pharmaceutical and therapeutic agents intravenously or subcutaneously for use in targeted pharmaceutical therapies for a wide range of medical purposes; drug delivery agents consisting of oligonucleotide compounds that facilitate the delivery of a wide range of pharmaceutical based therapies
No 90458999
No Service Mark
No
No
No
No
No
No
No
No
No
| Status Date | Action Taken |
|---|---|
| 12th Mar 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| 16th Jan 2024 | PUBLISHED FOR OPPOSITION |
| 16th Jan 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| 27th Dec 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| 13th Dec 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| 10th Nov 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| 10th Nov 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| 10th Nov 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| 10th Aug 2023 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| 10th Aug 2023 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
